Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

Plugin JSON Content Importer Pro not running: Check Licence! Check that a Licence is active for https://freeline.life
You might also like
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels